Inogen Announces Third Quarter 2022 Financial Results
Inogen reported a total revenue of $105.4 million for Q3 2022, marking a 13.2% increase year-over-year compared to $93.1 million in Q3 2021. On a constant currency basis, revenue growth was 14.5%. However, the company faced a GAAP net loss of $9.5 million and an adjusted net loss of $4.1 million. Total operating expenses rose 28.5% to $53.1 million. Despite these challenges, Inogen maintains a robust cash position of $209.6 million with no debt. For Q4 2022, revenue guidance is projected between $87 million and $92 million, indicating a potential growth of 14% to 20%.
- Total revenue increased 13.2% year-over-year to $105.4 million.
- Cash and cash equivalents stood at $209.6 million with no debt.
- Q4 2022 revenue guidance projected at $87-$92 million, indicating 14%-20% growth.
- GAAP net loss of $9.5 million compared to a net income of $12.2 million in Q3 2021.
- Adjusted net loss of $4.1 million, down from a net income of $14.4 million in Q3 2021.
- Total operating expenses increased 28.5% to $53.1 million.
Double Digit Year-over-Year Revenue Growth of
Constant Currency Year-over-Year Revenue Growth of
Third Quarter 2022 Highlights
-
Reported total revenue was
for the period ended$105.4 million September 30, 2022 , representing a13.2% increase from for the period ended$93.1 million September 30, 2021 . -
On a constant currency basis, total revenue for the period ended
September 30, 2022 , increased14.5% . -
GAAP net loss of
, adjusted net loss of$9.5 million , and adjusted EBITDA was a loss of$4.1 million .$1.2 million - Strong balance sheet and cash position.
“I am pleased with the progress the team has made on our transformational journey. We fulfilled customer demand by overcoming supply chain challenges through extraordinary efforts, resulting in year-over-year double digit revenue growth,” said
Third Quarter 2022 Financial Results
Third quarter total revenue increased
Total gross margin was
Total operating expense for the quarter was
GAAP net loss for the third quarter of 2022 was
Adjusted EBITDA was a negative
Cash and cash equivalents were
A reconciliation of adjusted EBITDA and adjusted net income (loss) for the three and nine months ended
Fourth Quarter 2022 Financial Guidance
Inogen now projects revenue for the fourth quarter of 2022 to be in the range of approximately
Conference Call
Individuals interested in listening to the conference call today at
US domestic callers (877) 841-3961
International callers (201) 689-8589
Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. This webcast will also be archived on the website for 6 months.
A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
About Inogen
Inogen is a medical technology company offering innovative respiratory products for use in the homecare setting. The Company primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the Company’s expectations related to its financial and operational results for the fourth quarter of 2022, expectations related to 2023 for growth as well as supply chain challenges; and expectations of future growth and profitability. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks arising from the possibility that Inogen will not realize anticipated revenue; risks related to the Company’s supply chain and limited availability of parts used in our POCs, the risk of further slowdowns or temporarily halts of production, or cost inflation for such components; the impact of changes in reimbursement rates and reimbursement and regulatory policies; the possible loss of key employees, customers, or suppliers; expenses and costs will exceed Inogen’s expectations; intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. In addition, Inogen's business is subject to numerous additional risks and uncertainties and information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the period ended
Non-GAAP Financial Measures
Inogen has presented certain financial information in accordance with
Consolidated Statements of Comprehensive Income (Loss) |
|
|||||||||||||||
(unaudited) |
|
|||||||||||||||
(amounts in thousands, except share and per share amounts) |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three months ended |
|
|
Nine months ended |
|
||||||||||
|
|
|
|
|
|
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Sales revenue |
|
$ |
90,672 |
|
|
$ |
80,974 |
|
|
$ |
247,365 |
|
|
$ |
248,359 |
|
Rental revenue |
|
|
14,717 |
|
|
|
12,131 |
|
|
|
41,785 |
|
|
|
33,241 |
|
Total revenue |
|
|
105,389 |
|
|
|
93,105 |
|
|
|
289,150 |
|
|
|
281,600 |
|
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of sales revenue |
|
|
55,891 |
|
|
|
40,437 |
|
|
|
146,052 |
|
|
|
129,637 |
|
Cost of rental revenue, including depreciation of |
|
|
6,700 |
|
|
|
4,981 |
|
|
|
19,036 |
|
|
|
14,068 |
|
Total cost of revenue |
|
|
62,591 |
|
|
|
45,418 |
|
|
|
165,088 |
|
|
|
143,705 |
|
Gross profit |
|
|
42,798 |
|
|
|
47,687 |
|
|
|
124,062 |
|
|
|
137,895 |
|
Operating expense |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
4,581 |
|
|
|
3,754 |
|
|
|
16,009 |
|
|
|
11,892 |
|
Sales and marketing |
|
|
33,734 |
|
|
|
28,301 |
|
|
|
92,161 |
|
|
|
83,109 |
|
General and administrative |
|
|
14,775 |
|
|
|
9,258 |
|
|
|
42,646 |
|
|
|
26,981 |
|
Total operating expense |
|
|
53,090 |
|
|
|
41,313 |
|
|
|
150,816 |
|
|
|
121,982 |
|
Income (loss) from operations |
|
|
(10,292 |
) |
|
|
6,374 |
|
|
|
(26,754 |
) |
|
|
15,913 |
|
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
868 |
|
|
|
21 |
|
|
|
1,122 |
|
|
|
107 |
|
Other expense |
|
|
(12 |
) |
|
|
(466 |
) |
|
|
(1,167 |
) |
|
|
(472 |
) |
Total other income (expense), net |
|
|
856 |
|
|
|
(445 |
) |
|
|
(45 |
) |
|
|
(365 |
) |
Income (loss) before provision (benefit) for income taxes |
|
|
(9,436 |
) |
|
|
5,929 |
|
|
|
(26,799 |
) |
|
|
15,548 |
|
Provision (benefit) for income taxes |
|
|
70 |
|
|
|
(6,245 |
) |
|
|
363 |
|
|
|
(996 |
) |
Net income (loss) |
|
$ |
(9,506 |
) |
|
$ |
12,174 |
|
|
$ |
(27,162 |
) |
|
$ |
16,544 |
|
Other comprehensive income (loss), net of tax |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Change in foreign currency translation adjustment |
|
|
(616 |
) |
|
|
(251 |
) |
|
|
(1,453 |
) |
|
|
(585 |
) |
Change in net unrealized gains (losses) on foreign currency hedging |
|
|
209 |
|
|
|
494 |
|
|
|
(1,669 |
) |
|
|
2,028 |
|
Less: reclassification adjustment for net (gains) losses included in net income |
|
|
— |
|
|
|
106 |
|
|
|
1,206 |
|
|
|
(267 |
) |
Total net change in unrealized gains (losses) on foreign currency hedging |
|
|
209 |
|
|
|
600 |
|
|
|
(463 |
) |
|
|
1,761 |
|
Change in net unrealized gains (losses) on marketable securities |
|
|
17 |
|
|
|
(1 |
) |
|
|
16 |
|
|
|
- |
|
Total other comprehensive income (loss), net of tax |
|
|
(390 |
) |
|
|
348 |
|
|
|
(1,900 |
) |
|
|
1,176 |
|
Comprehensive income (loss) |
|
$ |
(9,896 |
) |
|
$ |
12,522 |
|
|
$ |
(29,062 |
) |
|
$ |
17,720 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic net income (loss) per share attributable to common stockholders (1) |
|
$ |
(0.42 |
) |
|
$ |
0.54 |
|
|
$ |
(1.19 |
) |
|
$ |
0.74 |
|
Diluted net income (loss) per share attributable to common stockholders (1) (2) |
|
$ |
(0.42 |
) |
|
$ |
0.53 |
|
|
$ |
(1.19 |
) |
|
$ |
0.73 |
|
Weighted-average number of shares used in calculating net income (loss) per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic common shares |
|
|
22,882,333 |
|
|
|
22,619,272 |
|
|
|
22,827,733 |
|
|
|
22,416,575 |
|
Diluted common shares |
|
|
22,882,333 |
|
|
|
22,854,229 |
|
|
|
22,827,733 |
|
|
|
22,803,355 |
|
(1) |
|
Reconciliations of net income (loss) attributable to common stockholders basic and diluted can be found in Inogen’s Quarterly Report on Form 10-Q to be filed with the |
(2) |
|
Due to a net loss for the three and nine months ended |
Consolidated Balance Sheets |
|
|||||||
(unaudited) |
|
|||||||
(amounts in thousands) |
|
|||||||
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
|
2022 |
|
|
2021 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
209,633 |
|
|
$ |
235,524 |
|
Marketable securities |
|
|
- |
|
|
|
9,989 |
|
Accounts receivable, net |
|
|
50,533 |
|
|
|
24,452 |
|
Inventories, net |
|
|
35,725 |
|
|
|
31,873 |
|
Income tax receivable |
|
|
1,579 |
|
|
|
1,343 |
|
Prepaid expenses and other current assets |
|
|
20,306 |
|
|
|
26,005 |
|
Total current assets |
|
|
317,776 |
|
|
|
329,186 |
|
Property and equipment, net |
|
|
40,632 |
|
|
|
38,926 |
|
|
|
|
32,674 |
|
|
|
32,979 |
|
Intangible assets, net |
|
|
53,700 |
|
|
|
60,147 |
|
Operating lease right-of-use asset |
|
|
22,479 |
|
|
|
24,912 |
|
Other assets |
|
|
2,323 |
|
|
|
3,363 |
|
Total assets |
|
$ |
469,584 |
|
|
$ |
489,513 |
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable and accrued expenses |
|
$ |
33,512 |
|
|
$ |
25,689 |
|
Accrued payroll |
|
|
11,789 |
|
|
|
17,307 |
|
Warranty reserve - current |
|
|
7,830 |
|
|
|
6,480 |
|
Operating lease liability - current |
|
|
3,486 |
|
|
|
3,393 |
|
Deferred revenue - current |
|
|
9,119 |
|
|
|
8,568 |
|
Income tax payable |
|
|
- |
|
|
|
75 |
|
Total current liabilities |
|
|
65,736 |
|
|
|
61,512 |
|
Warranty reserve - noncurrent |
|
|
7,630 |
|
|
|
7,246 |
|
Operating lease liability - noncurrent |
|
|
20,662 |
|
|
|
23,281 |
|
Earnout liability - noncurrent |
|
|
13,687 |
|
|
|
15,386 |
|
Deferred revenue - noncurrent |
|
|
11,027 |
|
|
|
11,861 |
|
Total liabilities |
|
|
118,742 |
|
|
|
119,286 |
|
Stockholders' equity |
|
|
|
|
|
|
||
Common stock |
|
|
23 |
|
|
|
23 |
|
Additional paid-in capital |
|
|
309,140 |
|
|
|
299,463 |
|
Retained earnings |
|
|
42,110 |
|
|
|
69,272 |
|
Accumulated other comprehensive income (loss) |
|
|
(431 |
) |
|
|
1,469 |
|
Total stockholders' equity |
|
|
350,842 |
|
|
|
370,227 |
|
Total liabilities and stockholders' equity |
|
$ |
469,584 |
|
|
$ |
489,513 |
|
Condensed Consolidated Cash Flow |
|
|||||||
(unaudited) |
|
|||||||
(amounts in thousands) |
|
|||||||
|
|
|
|
|
|
|
||
|
|
Nine months ended |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Cash flows from operating activities |
|
|
|
|
|
|
||
Net income (loss) |
|
$ |
(27,162 |
) |
|
$ |
16,544 |
|
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
17,536 |
|
|
|
15,861 |
|
Loss on rental units and other fixed assets |
|
|
2,488 |
|
|
|
952 |
|
Gain on sale of former rental assets |
|
|
(93 |
) |
|
|
(59 |
) |
Provision for sales revenue returns and doubtful accounts |
|
|
10,816 |
|
|
|
8,248 |
|
Provision for rental revenue adjustments |
|
|
— |
|
|
|
3,543 |
|
Provision for inventory losses |
|
|
2,060 |
|
|
|
1,452 |
|
Stock-based compensation expense |
|
|
9,185 |
|
|
|
8,547 |
|
Deferred income taxes |
|
|
— |
|
|
|
(1,014 |
) |
Change in fair value of earnout liability |
|
|
(1,699 |
) |
|
|
(9,822 |
) |
Changes in operating assets and liabilities |
|
|
(35,181 |
) |
|
|
(27,117 |
) |
Net cash provided by (used in) operating activities |
|
|
(22,050 |
) |
|
|
17,135 |
|
Cash flows from investing activities |
|
|
|
|
|
|
||
Maturities of marketable securities |
|
|
10,005 |
|
|
|
15,705 |
|
Investment in intangible assets |
|
|
— |
|
|
|
(132 |
) |
Investment in property and equipment |
|
|
(2,770 |
) |
|
|
(4,807 |
) |
Production and purchase of rental equipment |
|
|
(11,320 |
) |
|
|
(13,156 |
) |
Proceeds from sale of former assets |
|
|
152 |
|
|
|
122 |
|
Net cash used in investing activities |
|
|
(3,933 |
) |
|
|
(2,268 |
) |
Cash flows from financing activities |
|
|
|
|
|
|
||
Proceeds from stock options exercised |
|
|
35 |
|
|
|
13,699 |
|
Proceeds from employee stock purchases |
|
|
1,691 |
|
|
|
1,948 |
|
Payment of employment taxes related to release of restricted stock |
|
|
(1,234 |
) |
|
|
(617 |
) |
Net cash provided by financing activities |
|
|
492 |
|
|
|
15,030 |
|
Effect of exchange rates on cash |
|
|
(400 |
) |
|
|
(283 |
) |
Net increase (decrease) in cash and cash equivalents |
|
$ |
(25,891 |
) |
|
$ |
29,614 |
|
Supplemental Financial Information |
|
|||||||||||||||
(unaudited) |
|
|||||||||||||||
(in thousands, except units and patients) |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three months ended |
|
|
Nine months ended |
|
||||||||||
|
|
|
|
|
|
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Revenue by region and category |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Business-to-business domestic sales |
|
$ |
42,546 |
|
|
$ |
22,793 |
|
|
$ |
58,859 |
|
|
$ |
81,094 |
|
Business-to-business international sales |
|
|
15,078 |
|
|
|
21,834 |
|
|
|
80,460 |
|
|
|
59,377 |
|
Direct-to-consumer domestic sales |
|
|
33,048 |
|
|
|
36,347 |
|
|
|
108,046 |
|
|
|
107,888 |
|
Direct-to-consumer domestic rentals |
|
|
14,717 |
|
|
|
12,131 |
|
|
|
41,785 |
|
|
|
33,241 |
|
Total revenue |
|
$ |
105,389 |
|
|
$ |
93,105 |
|
|
$ |
289,150 |
|
|
$ |
281,600 |
|
Additional financial measures |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Units sold |
|
|
54,200 |
|
|
|
44,600 |
|
|
|
127,000 |
|
|
|
146,400 |
|
Net rental patients as of period-end |
|
|
44,600 |
|
|
|
40,400 |
|
|
|
44,600 |
|
|
|
40,400 |
|
Reconciliation of |
|
|||||||||||||||
(unaudited) |
|
|||||||||||||||
(in thousands) |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three months ended |
|
|
Nine months ended |
|
||||||||||
|
|
|
|
|
|
|
||||||||||
Non-GAAP EBITDA and Adjusted EBITDA |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Net income (loss) (GAAP) |
|
$ |
(9,506 |
) |
|
$ |
12,174 |
|
|
$ |
(27,162 |
) |
|
$ |
16,544 |
|
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
(868 |
) |
|
|
(21 |
) |
|
|
(1,122 |
) |
|
|
(107 |
) |
Provision (benefit) for income taxes |
|
|
70 |
|
|
|
(6,245 |
) |
|
|
363 |
|
|
|
(996 |
) |
Depreciation and amortization |
|
|
5,928 |
|
|
|
5,522 |
|
|
|
17,536 |
|
|
|
15,861 |
|
EBITDA (non-GAAP) |
|
|
(4,376 |
) |
|
|
11,430 |
|
|
|
(10,385 |
) |
|
|
31,302 |
|
Stock-based compensation |
|
|
3,500 |
|
|
|
2,792 |
|
|
|
9,185 |
|
|
|
8,547 |
|
Change in fair value of earnout liability |
|
|
(288 |
) |
|
|
(2,052 |
) |
|
|
(1,699 |
) |
|
|
(9,869 |
) |
Adjusted EBITDA (non-GAAP) |
|
$ |
(1,164 |
) |
|
$ |
12,170 |
|
|
$ |
(2,899 |
) |
|
$ |
29,980 |
|
|
|
Three months ended |
|
|||||||||||||
|
|
Net Income (Loss) |
|
|
Diluted EPS |
|
||||||||||
Non-GAAP Adjusted Net Income (Loss) and Diluted EPS |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Financial Results (GAAP) |
|
$ |
(9,506 |
) |
|
$ |
12,174 |
|
|
$ |
(0.42 |
) |
|
$ |
0.53 |
|
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Amortization of intangibles |
|
|
2,150 |
|
|
|
2,155 |
|
|
|
|
|
|
|
||
Stock-based compensation |
|
|
3,500 |
|
|
|
2,792 |
|
|
|
|
|
|
|
||
Change in fair value of earnout liability |
|
|
(288 |
) |
|
|
(2,052 |
) |
|
|
|
|
|
|
||
Income tax impact of adjustments (1) |
|
|
- |
|
|
|
(695 |
) |
|
|
|
|
|
|
||
Adjusted |
|
$ |
(4,144 |
) |
|
$ |
14,374 |
|
|
$ |
(0.18 |
) |
|
$ |
0.63 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Nine months ended |
|
|||||||||||||
|
|
Net Income (Loss) |
|
|
Diluted EPS |
|
||||||||||
Non-GAAP Adjusted Net Income (Loss) and Diluted EPS |
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Financial Results (GAAP) |
|
$ |
(27,162 |
) |
|
$ |
16,544 |
|
|
$ |
(1.19 |
) |
|
$ |
0.73 |
|
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Amortization of intangibles |
|
|
6,447 |
|
|
|
6,622 |
|
|
|
|
|
|
|
||
Stock-based compensation |
|
|
9,185 |
|
|
|
8,547 |
|
|
|
|
|
|
|
||
Change in fair value of earnout liability |
|
|
(1,699 |
) |
|
|
(9,869 |
) |
|
|
|
|
|
|
||
Income tax impact of adjustments (1) |
|
|
- |
|
|
|
(1,272 |
) |
|
|
|
|
|
|
||
Adjusted |
|
$ |
(13,229 |
) |
|
$ |
20,572 |
|
|
$ |
(0.58 |
) |
|
$ |
0.90 |
|
(1) |
|
Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of |
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005392/en/
ir@inogen.net
Source:
FAQ
What were Inogen's Q3 2022 revenue figures?
What was Inogen's GAAP net loss for Q3 2022?
What is Inogen's revenue guidance for Q4 2022?
How much cash did Inogen have by the end of Q3 2022?